Selected
Highlights from the 9th International Workshop on Clinical Pharmacology of HIV
Therapy
The
9th International Workshop on Clinical Pharmacology of HIV Therapy
took place
April 7 - 9, 2008 in New Orleans, LA. Pharmacological factors are an important
cause of therapeutic failure during antiretroviral treatment. Inadequate exposure
of HIV to drugs may be caused by non-adherence, drug interactions and variations
in drug pharmacokinetics due to a variety of genetic and drug-specific characteristics.
The Workshop
on clinical pharmacology in New Orleans provided an update on various topics,
including newly detected drug-drug interactions, drug-induced toxicity, pharmacokinetics
of investigational agents, generic drug use in resource-poor countries, and post-marketing
surveillance projects. The workshop also presented the current state of the art
on predicting drug interactions, designing drug interaction studies, and performing
therapeutic drug monitoring (TDM).
This
edition of HIV and Hepatitis.com focuses on the data presented on the pharmacokinetics
of the new (FDA-approved) protease inhibitor darunavir
(Prezista), the FDA-approved next generation NNRTI etravirine
(Intelence), and the experimental next generation NNRTI TMC278.
Prezista
(darunavir)
